Bajaj Healthcare Q1 FY27 results: revenue Rs 165.6 cr, PAT Rs 13.7 cr

Exceptional ItemResults View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.8%Reaction day

₹391.00

prior close

₹390.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-6.1% vs market

Pharmaceuticals peers, median of 165sector+0.1%-5.9% vs sector

On the reaction day the stock moved 6.1 pts less than Nifty Microcap 250 and 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.7

10m

-5.1

15m

-4.7

30m

-4.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.8+0.3-6.1+0.1-5.9

Next day

-16.9-0.9-16.0-1.5-15.4

-18.7-1.5-17.2-2.1-16.6

-17.1-1.1-15.9-2.2-14.9

-18.2+0.2-18.4-1.5-16.7

-18.2-1.1-17.1-2.2-15.9

-16.8-1.2-15.7-2.6-14.2

15d

-16.0+3.1-19.2+0.3-16.4

-17.9+4.5-22.3-0.4-17.4

-14.3+4.5-18.8+1.3-15.6

-17.1-2.2-14.9-5.8-11.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bajaj Healthcare reported Q1 FY27 revenue of Rs 165.63 cr, up 11.3% YoY from Rs 148.84 cr. PAT stood at Rs 13.70 cr vs Rs 11.83 cr, up 15.7%. EPS was Rs 4.07 vs Rs 3.74. Walker Chandiok gave an unmodified limited review. The board also approved continuation of independent director Gopalakrishnan Kesavan beyond age 75, pending shareholder approval.

Likely market impact

Steady YoY growth in both revenue and profit. Discontinued operations continue to drag. Awaiting shareholder nod on director continuation.